TapImmune (NASDAQ:MRKR) and LifeVantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
This is a breakdown of current recommendations for TapImmune and LifeVantage, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares TapImmune and LifeVantage’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
36.9% of TapImmune shares are held by institutional investors. Comparatively, 41.0% of LifeVantage shares are held by institutional investors. 23.7% of TapImmune shares are held by company insiders. Comparatively, 3.9% of LifeVantage shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares TapImmune and LifeVantage’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|LifeVantage||$225.96 million||0.81||$7.43 million||$0.59||22.05|
LifeVantage has higher revenue and earnings than TapImmune. TapImmune is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
TapImmune has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, LifeVantage has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.
LifeVantage beats TapImmune on 9 of the 14 factors compared between the two stocks.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is developing TPIV100/110, which is in Phase II clinical trial to treat human epidermal growth factor receptor 2 breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. It is also developing a proprietary nucleic acid-based antigen expression technology, PolyStart, to improve the ability of the immune system to recognize and destroy diseased cells. The company is headquartered in Houston, Texas.
LifeVantage Corporation engages in the identification, research, development, and distribution of nutraceutical dietary supplements and skin care products. The company offers Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skin care product; Axio, a line of energy drink mixes; Omega+, a fish oil dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3; and PhysIQ, a weight management system, as well as Petandim for Dogs, a companion pet supplement formulated to treat oxidative stress in dogs. It also provides skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, and micro-lift serums; and Hair Care System under the TrueScience brand name. The company sells its products through a direct sales model, as well as a network of independent distributors in the United States, Japan, Hong Kong, Australia, Canada, Mexico, Thailand, the United Kingdom, the Netherlands, Germany, Spain, and Taiwan. LifeVantage Corporation is headquartered in Sandy, Utah.
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.